Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome

Journal of Proteome Research

Volumn 8, Issue 10, 2009, Pages 4428-4440

  Wang, Chih Liang ^a,b   Wang, Chun I ^b   Liao, Pao Chi ^c   Chen, Chi De ^b   Liang, Ying ^b   Chuang, Wen Yu ^a   Tsai, Ying Huang ^a   Chen, Hua Chien ^b   Chang, Yu Sun ^b   Yu, Jau Song ^b   Wu, Chih Ching ^b   Yu, Chia Jung ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Biomarker; Nonsmall cell lung cancer; Pleural effusion; Retinoblastoma associated binding protein 46; Secretome

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; MESSENGER RNA; PROTEOME; RETINOBLASTOMA ASSOCIATED BINDING PROTEIN 46; RETINOBLASTOMA PROTEIN; SECRETOME; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CELL MIGRATION; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GEL ELECTROPHORESIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; TISSUE LEVEL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PROTEINS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; RETINOBLASTOMA-BINDING PROTEIN 7; STATISTICS, NONPARAMETRIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 70349972788     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr900160h     Document Type: Article

References (78)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M. J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58 (2), 71-96.
2. Charloux, A.; Quoix, E.; Wolkove, N.; Small, D.; Pauli, G.; Kreisman, H. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int. J. Epidemiol. 1997, 26 (1), 14-23. (Pubitemid 27129564)
3. Mulshine, J. L.; Sullivan, D. C. Clinical practice. N. Engl. J. Med. 2005, 352 (26), 2714-2720.
4. Bach, P. B.; Silvestri, G. A.; Hanger, M.; Jett, J. R. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132 (3 Suppl), 69S-77S.
5. Silvestri, G. A.; Gould, M. K.; Margolis, M. L.; Tanoue, L. T.; McCrory, D.; Toloza, E.; Detterbeck, F. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007, 132 (3 Suppl), 178S-201S. (Pubitemid 47494403)
6. Wahidi, M. M.; Govert, J. A.; Goudar, R. K.; Gould, M. K.; McCrory, D. C. Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132 (3 Suppl), 94S-107S.
7. Ferrigno, D.; Buccheri, G.; Biggi, A. Serum tumour markers in lung cancer: history, biology and clinical applications. Eur. Respir. J. 1994, 7 (1), 186-197. (Pubitemid 24075144)
8. Schneider, J. Tumor markers in detection of lung cancer. Adv. Clin. Chem. 2006, 42, 1-41. (Pubitemid 44302105)
9. Pfister, D. G.; Johnson, D. H.; Azzoli, C. G.; Sause, W.; Smith, T. J.; Baker, S., Jr.; Olak, J.; Stover, D.; Strawn, J. R.; Turrisi, A. T.; Somerfield, M. R. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. 2004, 22 (2), 330-353.
10. Anderson, N. L.; Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1 (11), 845-867.
11. Good, D. M.; Thongboonkerd, V.; Novak, J.; Bascands, J. L.; Schanstra, J. P.; Coon, J. J.; Dominiczak, A.; Mischak, H. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J. Proteome Res. 2007, 6 (12), 4549-4555.
12. Wu, C. C.; Chen, H. C.; Chen, S. J.; Liu, H. P.; Hsieh, Y. Y.; Yu, C. J.; Tang, R.; Hsieh, L. L.; Yu, J. S.; Chang, Y. S. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 2008, 8 (2), 316-332.
13. Weng, L. P.; Wu, C. C.; Hsu, B. L.; Chi, L. M.; Liang, Y.; Tseng, C. P.; Hsieh, L. L.; Yu, J. S. Secretome-based identification of Mac-2 binding protein as a potential oral cancer marker involved in cell growth and motility. J. Proteome Res. 2008, 7 (9), 3765-3775.
14. Pardo, M.; Garcia, A.; Antrobus, R.; Blanco, M. J.; Dwek, R. A.; Zitzmann, N. Biomarker discovery from uveal melanoma secretomes: identification of gp100 and cathepsin D in patient serum. J. Proteome Res. 2007, 6 (7), 2802-2811. (Pubitemid 47122374)
15. Kim, J. E.; Koo, K. H.; Kim, Y. H.; Sohn, J.; Park, Y. G. Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model. Exp. Mol. Med. 2008, 40 (6), 709-720.
16. Faca, V. M.; Hanash, S. M. In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. Cancer Res. 2009, 69 (3), 728-730.
17. Xue, H.; Lu, B.; Lai, M. The cancer secretome: a reservoir of biomarkers. J. Transl. Med. 2008, 6, 52.
18. Simpson, R. J.; Bernhard, O. K.; Greening, D. W.; Moritz, R. L. Proteomics-driven cancer biomarker discovery: looking to the future. Curr. Opin. Chem. Biol. 2008, 12 (1), 72-77.
19. Chen, S. T.; Pan, T. L.; Juan, H. F.; Chen, T. Y.; Lin, Y. S.; Huang, C. M. Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. J. Proteome Res. 2008, 7 (4), 1379-1387.
20. Andrews, C. O.; Gora, M. L. Pleural effusions: pathophysiology and management. Ann. Pharmacother. 1994, 28 (7-8), 894-903.
21. Shijubo, N.; Honda, Y.; Fujishima, T.; Takahashi, H.; Kodama, T.; Kuroki, Y.; Akino, T.; Abe, S. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma. Eur. Respir. J. 1995, 8 (3), 403-406.
22. Domej, W.; Tilz, G. P.; Foldes-Papp, Z.; Demel, U.; Rabold, T.; Holzer, H. Cystatin C of pleural effusion as a novel diagnostic aid in pleural diseases of different aetiologies. Clin. Sci. 2002, 102 (3), 373-380. (Pubitemid 34214401)
23. Cheng, D.; Rodriguez, R. M.; Perkett, E. A.; Rogers, J.; Bienvenu, G.; Lappalainen, U.; Light, R. W. Vascular endothelial growth factor in pleural fluid. Chest 1999, 116 (3), 760-765. (Pubitemid 29428497)
24. Hsieh, W. Y.; Chen, M. W.; Ho, H. T.; You, T. M.; Lu, Y. T. Identification of differentially expressed proteins in human malignant pleural effusions. Eur. Respir. J. 2006, 28 (6), 1178-1185. (Pubitemid 44883853)
25. Bard, M. P.; Hegmans, J. P.; Hemmes, A.; Luider, T. M.; Willemsen, R.; Severijnen, L. A.; van Meerbeeck, J. P.; Burgers, S. A.; Hoogsteden, H. C.; Lambrecht, B. N. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am. J. Respir. Cell Mol. Biol. 2004, 31 (1), 114-121. (Pubitemid 38888047)
26. DeCamp, M. M., Jr.; Mentzer, S. J.; Swanson, S. J.; Sugarbaker, D. J. Malignant effusive disease of the pleura and pericardium. Chest 1997, 112 (4 Suppl), 291S-295S.
27. Tyan, Y. C.; Wu, H. Y.; Su, W. C.; Chen, P. W.; Liao, P. C. Proteomic analysis of human pleural effusion. Proteomics 2005, 5 (4), 1062-1074. (Pubitemid 40469035)
28. Tyan, Y. C.; Wu, H. Y.; Lai, W. W.; Su, W. C.; Liao, P. C. Proteomic profiling of human pleural effusion using two-dimensional nano liquid chromatography tandem mass spectrometry. J. Proteome Res. 2005, 4 (4), 1274-1286. (Pubitemid 41208682)
29. Tyan, Y. C.; Liao, P. C. Proteomics analysis of serous fluids and effusions: Pleural, pericardial, and peritoneal. Proteomics Clin. Appl. 2007, 1 (8), 834-844.
30. Chu, Y. W.; Yang, P. C.; Yang, S. C.; Shyu, Y. C.; Hendrix, M. J.; Wu, R.; Wu, C. W. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am. J. Respir. Cell Mol. Biol. 1997, 17 (3), 353-360. (Pubitemid 127500840)
31. Wu, C. C.; Chien, K. Y.; Tsang, N. M.; Chang, K. P.; Hao, S. P.; Tsao, C. H.; Chang, Y. S.; Yu, J. S. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 2005, 5 (12), 3173-3182.
32. Olsen, J. V.; de Godoy, L. M.; Li, G.; Macek, B.; Mortensen, P.; Pesch, R.; Makarov, A.; Lange, O.; Horning, S.; Mann, M. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol. Cell. Proteomics 2005, 4 (12), 2010-2021. (Pubitemid 41830195)
33. Keller, A.; Nesvizhskii, A. I.; Kolker, E.; Aebersold, R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 2002, 74 (20), 5383-5392. (Pubitemid 35215372)
34. Nesvizhskii, A. I.; Keller, A.; Kolker, E.; Aebersold, R. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 2003, 75 (17), 4646-4658. (Pubitemid 37082259)
35. Bendtsen, J. D.; Nielsen, H.; von Heijne, G.; Brunak, S. Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 2004, 340 (4), 783-795. (Pubitemid 38829638)
36. Nielsen, H.; Krogh, A. Prediction of signal peptides and signal anchors by a hidden Markov model. Proc. Int. Conf. Intell. Syst. Mol. Biol. 1998, 6, 122-130.
37. Bendtsen, J. D.; Jensen, L. J.; Blom, N.; Von Heijne, G.; Brunak, S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng. Des. Sel. 2004, 17 (4), 349-356. (Pubitemid 39093515)
38. Moller, S.; Croning, M. D.; Apweiler, R. Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics 2001, 17 (7), 646-653. (Pubitemid 32707587)
39. Ishihama, Y.; Oda, Y.; Tabata, T.; Sato, T.; Nagasu, T.; Rappsilber, J.; Mann, M. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol. Cell. Proteomics 2005, 4 (9), 1265-1272. (Pubitemid 41448714)
40. Zhang, Y.; Adachi, J.; Olsen, J. V.; Shi, R.; de Souza, G.; Pasini, E.; Foster, L. J.; Macek, B.; Zougman, A.; Kumar, C.; Wisniewski, J. R.; Jun, W.; Mann, M. MAPU: Max-Planck Unified database of organellar, cellular, tissue and body fluid proteomes. Nucleic Acids Res. 2007, 35 (Database issue), D771-779.
41. Hanley, J. A.; McNeil, B. J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148 (3), 839-843.
42. Youden, W. J. Index for rating diagnostic tests. Cancer 1950, 3 (1), 32-35.
43. Huang, S.; Lee, W. H.; Lee, E. Y. A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product. Nature 1991, 350 (6314), 160-162.
44. Zhang, Y.; Ng, H. H.; Erdjument-Bromage, H.; Tempst, P.; Bird, A.; Reinberg, D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 1999, 13 (15), 1924-1935. (Pubitemid 29407360)
45. Guan, L. S.; Rauchman, M.; Wang, Z. Y. Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition. J. Biol. Chem. 1998, 273 (42), 27047-27050.
46. Guan, L. S.; Li, G. C.; Chen, C. C.; Liu, L. Q.; Wang, Z. Y. Rb-associated protein 46 (RbAp46) suppresses the tumorigenicity of adenovirus-transformed human embryonic kidney 293 cells. Int. J. Cancer 2001, 93 (3), 333-338.
47. Li, G. C.; Guan, L. S.; Wang, Z. Y. Overexpression of RbAp46 facilitates stress-induced apoptosis and suppresses tumorigenicity of neoplastigenic breast epithelial cells. Int. J. Cancer 2003, 105 (6), 762-768.
48. Zhang, T. F.; Yu, S. Q.; Loggie, B. W.; Wang, Z. Y. Inducible expression of RbAp46 activates c-Jun NH2-terminal kinase-dependent apoptosis and suppresses progressive growth of tumor xenografts in nude mice. Anticancer Res. 2003, 23 (6C), 4621-4627.
49. Zhang, T. F.; Yu, S. Q.; Deuel, T. F.; Wang, Z. Y. Constitutive expression of Rb associated protein 46 (RbAp46) reverts transformed phenotypes of breast cancer cells. Anticancer Res. 2003, 23 (5A), 3735-3740.
50. Hu, S. Y.; Chen, Z. X.; Gu, W. Y.; Cen, J. N.; Zhao, Y.; Gu, M. [Detection of RbAp46 expression in bone marrow cells of leukemia patients by real-time quantitative RT-PCR]. Zhonghua Xueyexue Zazhi 2005, 26 (7), 417-420.
51. Thakur, A.; Rahman, K. W.; Wu, J.; Bollig, A.; Biliran, H.; Lin, X.; Nassar, H.; Grignon, D. J.; Sarkar, F. H.; Liao, J. D. Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer. Mol. Cancer Res. 2007, 5 (2), 171-181.
52. Engels, K.; Knauer, S. K.; Metzler, D.; Simf, C.; Struschka, O.; Bier, C.; Mann, W.; Kovacs, A. F.; Stauber, R. H. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J. Pathol. 2007, 211 (5), 532-540.
53. Nakatsuka, S.; Oji, Y.; Horiuchi, T.; Kanda, T.; Kitagawa, M.; Takeuchi, T.; Kawano, K.; Kuwae, Y.; Yamauchi, A.; Okumura, M.; Kitamura, Y.; Oka, Y.; Kawase, I.; Sugiyama, H.; Aozasa, K. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod. Pathol. 2006, 19 (6), 804-814. (Pubitemid 43780450)
54. Perren, A.; Komminoth, P.; Saremaslani, P.; Matter, C.; Feurer, S.; Lees, J. A.; Heitz, P. U.; Eng, C. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol. 2000, 157 (4), 1097-1103.
55. Colombo, E.; Martinelli, P.; Zamponi, R.; Shing, D. C.; Bonetti, P.; Luzi, L.; Volorio, S.; Bernard, L.; Pruneri, G.; Alcalay, M.; Pelicci, P. G. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res. 2006, 66 (6), 3044-3050.
56. Zacksenhaus, E.; Bremner, R.; Phillips, R. A.; Gallie, B. L. A bipartite nuclear localization signal in the retinoblastoma gene product and its importance for biological activity. Mol. Cell. Biol. 1993, 13 (8), 4588-4599. (Pubitemid 23220366)
57. Youn, J. H.; Shin, J. S. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J. Immunol. 2006, 177 (11), 7889-7897.
58. Belani, C. P.; Marts, S.; Schiller, J.; Socinski, M. A. Women and lung cancer: epidemiology, tumor biology, and emerging trends in clinical research. Lung Cancer 2007, 55 (1), 15-23.
59. Little, A. G.; Gay, E. G.; Gaspar, L. E.; Stewart, A. K. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer 2007, 57 (3), 253-260.
60. Guadagni, F.; Roselli, M.; Cosimelli, M.; Spila, A.; Cavaliere, F.; Arcuri, R.; D'Alessandro, R.; Fracasso, P. L.; Casale, V.; Vecchione, A.; Casciani, C. U.; Greiner, J. W.; Schlom, J. Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation. Int. J. Cancer. 1997, 72 (6), 949-954. (Pubitemid 27433556)
61. Weir, E. G.; Partin, A. W.; Epstein, J. I. Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J. Urol. 2000, 163 (6), 1739-1742.
62. Ogawa, M.; Yanoma, S.; Nagashima, Y.; Okamoto, N.; Ishikawa, H.; Haruki, A.; Miyagi, E.; Takahashi, T.; Hirahara, F.; Miyagi, Y. Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intrauterine growth restriction: possible interaction and correlation with glypican-3 hold the key. Placenta 2007, 28 (2-3), 224-232.
63. Oue, N.; Kuniyasu, H.; Noguchi, T.; Sentani, K.; Ito, M.; Tanaka, S.; Setoyama, T.; Sakakura, C.; Natsugoe, S.; Yasui, W. Serum concentration of Reg IV in patients with colorectal cancer: overexpression and high serum levels of Reg IV are associated with liver metastasis. Oncology 2007, 72 (5-6), 371-380.
64. Andersen, T. I.; Paus, E.; Nesland, J. M.; McKenzie, S. J.; Borresen, A. L. Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumor. Acta. Oncol. 1995, 34 (4), 499-504.
65. Binder, C.; Simon, A.; Binder, L.; Hagemann, T.; Schulz, M.; Emons, G.; Trumper, L.; Einspanier, A. Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Res. Treat. 2004, 87 (2), 157-166.
66. Bernstein, J. L.; Godbold, J. H.; Raptis, G.; Watson, M. A.; Levinson, B.; Aaronson, S. A.; Fleming, T. P. Identification of mammaglobin as a novel serum marker for breast cancer. Clin. Cancer Res. 2005, 11 (18), 6528-6535.
67. Macher-Goeppinger, S.; Aulmann, S.; Wagener, N.; Funke, B.; Tagscherer, K. E.; Haferkamp, A.; Hohenfellner, M.; Kim, S.; Autschbach, F.; Schirmacher, P.; Roth, W. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 2008, 10 (10), 1049-1056.
68. Stamey, T. A.; Freiha, F. S.; McNeal, J. E.; Redwine, E. A.; Whittemore, A. S.; Schmid, H. P. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993, 71 (3 Suppl), 933-938.
69. Guo, Y. J.; Liu, G.; Wang, X.; Jin, D.; Wu, M.; Ma, J.; Sy, M. S. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 1994, 54 (2), 422-426.
70. Molina, R.; Jo, J.; Filella, X.; Zanon, G.; Pahisa, J.; Munoz, M.; Farrus, B.; Latre, M. L.; Gimenez, N.; Hage, M.; Estape, J.; Ballesta, A. M. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res. 1996, 16 (4B), 2295-2300.
71. Singhal, H.; Bautista, D. S.; Tonkin, K. S.; O'Malley, F. P.; Tuck, A. B.; Chambers, A. F.; Harris, J. F. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer Res. 1997, 3 (4), 605-611.
72. Krainer, M.; Brodowicz, T.; Zeillinger, R.; Wiltschke, C.; Scholten, C.; Seifert, M.; Kubista, E.; Zielinski, C. C. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 1997, 54 (6), 475-481.
73. Li, G. C.; Wang, Z. Y. Constitutive expression of RbAp46 induces epithelial-mesenchymal transition in mammary epithelial cells. Anticancer Res. 2006, 26 (5A), 3555-3560.
74. Toh, Y.; Pencil, S.; Nicolson, G. A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J. Biol. Chem. 1994, 269 (37), 22958-22963.
75. Toh, Y.; Oki, E.; Oda, S.; Tokunaga, E.; Ohno, S.; Maehara, Y.; Nicolson, G. L.; Sugimachi, K. Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int. J. Cancer 1997, 74 (4), 459-463.
76. Toh, Y.; Kuwano, H.; Mori, M.; Nicolson, G. L.; Sugimachi, K. Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. Br. J. Cancer 1999, 79 (11-12), 1723-1726.
77. Ji, Y.; Zhang, P.; Lu, Y.; Ma, D. Expression of MTA2 gene in ovarian epithelial cancer and its clinical implication. J. Huazhong Univ. Sci. Technol., Med. Sci. 2006, 26 (3), 359-362.
78. Yao, Y. L.; Yang, W. M. The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. J. Biol. Chem. 2003, 278 (43), 42560-42568.